$ELOX
Eloxx Pharmaceuticals, Inc. Stock $elox

$elox Overview Financials Valuation SEC Filings Company Website

2013 Q3 Form 10-K Financial Statement

#000114420413050259 Filed on September 11, 2013

Income Statement

Concept	2013 Q3	2013	2012 Q2
Revenue	$100.0K	$7.819K	$0.00
YoY Change		-96.09%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$860.0K	$2.210M	$530.0K
YoY Change	28.36%	-18.75%	-15.87%
% of Gross Profit
Research & Development	$810.9K	$2.087M	$640.0K
YoY Change	57.94%	-18.69%	8.47%
% of Gross Profit
Depreciation & Amortization	$70.00K	$2.583K	$70.00K
YoY Change	16.67%	8.26%	133.33%
% of Gross Profit
Operating Expenses	$810.9K	$2.087M	$1.250M
YoY Change	57.94%	-18.69%	0.0%
Operating Profit	-$1.753M	-$4.651M
YoY Change	40.65%	-14.06%
Interest Expense	-$31.60K	-$119.1K	$130.0K
YoY Change	-7.0%	-6.28%	0.0%
% of Operating Profit
Other Income/Expense, Net		-$1.720M	$0.00
YoY Change
Pretax Income	-$1.780M	-$6.120M	-$1.440M
YoY Change	-14.83%	20.71%	-46.86%
Income Tax		$0.00	$0.00
% Of Pretax Income
Net Earnings	-$1.784M	-$6.123M	-$1.440M
YoY Change	-14.44%	20.85%	-46.86%
Net Earnings / Revenue	-1784.33%	-78303.39%
Basic Earnings Per Share
Diluted Earnings Per Share	-$14.83M	-$87.43M	-$28.80M
COMMON SHARES
Basic Shares Outstanding	231.9M shares		93.72M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2013 Q3	2013	2012 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$790.0K	$1.600M	$2.000M
YoY Change	-39.69%	-20.0%	-44.6%
Cash & Equivalents	$789.2K	$1.600M	$2.001M
Short-Term Investments
Other Short-Term Assets	$1.570M	$1.920M	$1.550M
YoY Change	7.53%	23.87%	6.9%
Inventory
Prepaid Expenses	$1.567M		$1.549M
Receivables		$40.00K
Other Receivables		$0.00
Total Short-Term Assets	$2.356M	$3.520M	$3.550M
YoY Change	-15.01%	-0.85%	-29.79%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.032K	$0.00	$5.857K
YoY Change	-37.88%	-100.0%	54.87%
Goodwill
YoY Change
Intangibles	$3.450M		$3.394M
YoY Change	-0.77%		-3.71%
Long-Term Investments
YoY Change
Other Assets	$10.00K	$10.00K	$10.00K
YoY Change	0.0%	0.0%	0.0%
Total Long-Term Assets	$3.459M	$3.580M	$3.405M
YoY Change	-0.84%	5.29%	-3.84%
TOTAL ASSETS
Total Short-Term Assets	$2.356M	$3.520M	$3.550M
Total Long-Term Assets	$3.459M	$3.580M	$3.405M
Total Assets	$5.815M	$7.100M	$6.955M
YoY Change	-7.11%	2.16%	-19.1%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.004M	$640.0K	$594.5K
YoY Change	7.69%	8.47%	6.25%
Accrued Expenses	$406.8K	$390.0K	$369.7K
YoY Change	33.38%	5.41%	-27.48%
Deferred Revenue
YoY Change
Short-Term Debt	$2.190M	$2.190M	$2.200M
YoY Change	-0.45%	-0.45%	0.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.598M	$3.210M	$3.163M
YoY Change	4.7%	1.58%	-3.22%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$99.73K	$100.0K	$99.73K
YoY Change	0.0%	-70.59%	0.0%
Total Long-Term Liabilities	$99.73K	$100.0K	$99.73K
YoY Change	0.0%	-70.59%	0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.598M	$3.210M	$3.163M
Total Long-Term Liabilities	$99.73K	$100.0K	$99.73K
Total Liabilities	$3.697M	$3.310M	$3.502M
YoY Change	1.84%	-5.43%	-14.16%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock	$23.48K		$941.1K
YoY Change	-97.99%		21.01%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$2.117M	$3.790M	$3.453M
YoY Change
Total Liabilities & Shareholders Equity	$5.815M	$7.100M	$6.955M
YoY Change	-7.11%	2.16%	-19.1%

Cashflow Statement

Concept	2013 Q3	2013	2012 Q2
OPERATING ACTIVITIES
Net Income	-$1.784M	-$6.123M	-$1.440M
YoY Change	-14.44%	20.85%	-46.86%
Depreciation, Depletion And Amortization	$70.00K	$2.583K	$70.00K
YoY Change	16.67%	8.26%	133.33%
Cash From Operating Activities	-$670.5K	-$3.903M	-$1.110M
YoY Change	5.34%	-11.02%	8.82%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$1.281K	-$110.0K
YoY Change	-100.0%	-71.28%	-56.0%
Acquisitions
YoY Change
Other Investing Activities		$1.270M	$0.00
YoY Change
Cash From Investing Activities	-$142.9K	-$529.0K	-$110.0K
YoY Change	-2.76%	17.44%	-56.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$290.00	$4.033M	10.00K
YoY Change	-99.69%	24.93%	-50.0%
NET CHANGE
Cash From Operating Activities	-$670.5K	-$3.903M	-1.110M
Cash From Investing Activities	-$142.9K	-$529.0K	-110.0K
Cash From Financing Activities	$290.00	$4.033M	10.00K
Net Change In Cash	-$813.1K	-$399.0K	-1.210M
YoY Change	17.97%	-75.19%	-3.2%
FREE CASH FLOW
Cash From Operating Activities	-$670.5K	-$3.903M	-$1.110M
Capital Expenditures	$0.00	$1.281K	-$110.0K
Free Cash Flow	-$670.5K	-$3.904M	-$1.000M
YoY Change	5.13%	-11.08%	29.87%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	231901368	shares
CY2013	dei	Entity Registrant Name EntityRegistrantName	SENESCO TECHNOLOGIES INC
CY2013	dei	Entity Central Index Key EntityCentralIndexKey	0001035354
CY2013	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2013	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
CY2013	dei	Document Period End Date DocumentPeriodEndDate	2013-06-30
CY2013	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2013	dei	Amendment Flag AmendmentFlag	false
CY2013	dei	Document Type DocumentType	10-K
CY2012	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	472463	USD
CY2011	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	609239	USD
CY2013	dei	Trading Symbol TradingSymbol	SNTI
CY2013	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2013	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
	us-gaap	Operating Income Loss OperatingIncomeLoss	-57620006	USD
CY2012	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	0	USD
CY2012Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2013Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2012Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2013Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2012Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2013	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2013	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2012Q4	dei	Entity Public Float EntityPublicFloat	15723026	USD
CY2013Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2013Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2012Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2013Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	227206174	shares
CY2013Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	227206174	shares
CY2012Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	94112483	shares
CY2012Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	94112483	shares
CY2013Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1602294	USD
CY2012Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2001325	USD
CY2013Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1919220	USD
CY2012Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1548524	USD
CY2013Q2	us-gaap	Assets Current AssetsCurrent	3521514	USD
CY2012Q2	us-gaap	Assets Current AssetsCurrent	3549849	USD
CY2013Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4555	USD
CY2012Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5857	USD
CY2013Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3566497	USD
CY2012Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3393992	USD
CY2013Q2	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	5171	USD
CY2012Q2	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	5171	USD
CY2013Q2	us-gaap	Assets Assets	7097737	USD
CY2012Q2	us-gaap	Assets Assets	6954869	USD
CY2013Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	637320	USD
CY2012Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	594514	USD
CY2013Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	387540	USD
CY2012Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	369695	USD
CY2013Q2	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	2187082	USD
CY2012Q2	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	2199108	USD
CY2013Q2	us-gaap	Liabilities Current LiabilitiesCurrent	3211942	USD
CY2012Q2	us-gaap	Liabilities Current LiabilitiesCurrent	3163317	USD
CY2013Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	0	USD
CY2012Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	238796	USD
CY2013Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	99728	USD
CY2012Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	99728	USD
CY2013Q2	us-gaap	Liabilities Liabilities	3311670	USD
CY2012Q2	us-gaap	Liabilities Liabilities	3501841	USD
CY2013Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2012Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q2	us-gaap	Common Stock Value CommonStockValue	2272062	USD
CY2012Q2	us-gaap	Common Stock Value CommonStockValue	941125	USD
CY2013Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	75939832	USD
CY2012Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	69952152	USD
CY2013Q2	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	74425835	USD
CY2012Q2	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	67440295	USD
CY2013Q2	us-gaap	Stockholders Equity StockholdersEquity	3786067	USD
CY2012Q2	us-gaap	Stockholders Equity StockholdersEquity	3453028	USD
CY2013Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7097737	USD
CY2012Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6954869	USD
CY2013	us-gaap	Licenses Revenue LicensesRevenue	0	USD
CY2012	us-gaap	Licenses Revenue LicensesRevenue	200000	USD
CY2011	us-gaap	Licenses Revenue LicensesRevenue	0	USD
	us-gaap	Licenses Revenue LicensesRevenue	1790000	USD
CY2013	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2499624	USD
CY2012	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2724144	USD
CY2011	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2610222	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	34114301	USD
CY2013	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2086666	USD
CY2012	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2566247	USD
CY2011	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3720394	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	23322271	USD
CY2013	us-gaap	Costs And Expenses CostsAndExpenses	4650500	USD
CY2012	us-gaap	Costs And Expenses CostsAndExpenses	5611528	USD
CY2011	us-gaap	Costs And Expenses CostsAndExpenses	7918703	USD
	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	8701721	USD
CY2013	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses	0	USD
CY2012	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses	0	USD
CY2013	us-gaap	Revenue From Grants RevenueFromGrants	0	USD
CY2012	us-gaap	Revenue From Grants RevenueFromGrants	0	USD
CY2011	us-gaap	Revenue From Grants RevenueFromGrants	244479	USD
	us-gaap	Revenue From Grants RevenueFromGrants	244479	USD
CY2012	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	0	USD
CY2011	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	0	USD
CY2013	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	371591	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	11227870	USD
CY2013	us-gaap	Interest Expense Debt InterestExpenseDebt	0	USD
CY2012	us-gaap	Interest Expense Debt InterestExpenseDebt	0	USD
CY2011	us-gaap	Interest Expense Debt InterestExpenseDebt	0	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	2027930	USD
CY2013	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-119087	USD
CY2012	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-127068	USD
CY2011	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-88122	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	164901	USD
	us-gaap	Costs And Expenses CostsAndExpenses	59410006	USD
CY2013	us-gaap	Operating Income Loss OperatingIncomeLoss	-4650500	USD
CY2012	us-gaap	Operating Income Loss OperatingIncomeLoss	-5411528	USD
CY2011	us-gaap	Operating Income Loss OperatingIncomeLoss	-7918703	USD
CY2011	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses	0	USD
	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses	586442	USD
CY2013	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	0	USD
CY2012	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	0	USD
CY2011	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-115869	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	205390	USD
CY2013	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2012	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2011	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-361877	USD
CY2013	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	0	USD
CY2013	us-gaap	Net Income Loss NetIncomeLoss	-6122542	USD
CY2012	us-gaap	Net Income Loss NetIncomeLoss	-5066133	USD
CY2011	us-gaap	Net Income Loss NetIncomeLoss	-7268976	USD
	us-gaap	Net Income Loss NetIncomeLoss	-63059296	USD
CY2013	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	862998	USD
CY2012	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	1625727	USD
CY2011	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	2638300	USD
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	11366539	USD
CY2013	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6985540	USD
CY2012	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6691860	USD
CY2011	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9907276	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-74425835	USD
CY2013	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	0	USD
CY2012	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	0	USD
CY2011	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	0	USD
CY2013	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6985540	USD
CY2012	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6691860	USD
CY2011	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9907276	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-74425835	USD
CY2010	snti	Common Stock Issued Upon Exercise Of Warrant Price Per Share CommonStockIssuedUponExerciseOfWarrantPricePerShare	0.01
CY1999	snti	Capital Contributed CapitalContributed	85179	USD
CY2006	snti	Common Stock Issued Upon Exercise Of Warrant Price Per Share CommonStockIssuedUponExerciseOfWarrantPricePerShare	0.01
CY2009	snti	Common Stock Issued Upon Exercise Of Warrant Price Per Share CommonStockIssuedUponExerciseOfWarrantPricePerShare	0.01
CY2002	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	1848726	USD
CY2003	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	848842	USD
CY2002	us-gaap	Net Income Loss NetIncomeLoss	-3021709	USD
CY2003	us-gaap	Net Income Loss NetIncomeLoss	-2778004	USD
CY2002Q2	us-gaap	Stockholders Equity StockholdersEquity	4785676	USD
CY2003Q2	us-gaap	Stockholders Equity StockholdersEquity	2856514	USD
CY2013	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.05
CY2012	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.08
CY2011	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.14
CY2013	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	136638419	shares
CY2012	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	85703291	shares
CY2011	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	69332447	shares
CY2013	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	64210	USD
CY2012	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	321137	USD
CY2011	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	1588087	USD
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	1973434	USD
CY2013	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-1724546	USD
CY2011	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	0	USD
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-1724546	USD
CY1999	us-gaap	Net Income Loss NetIncomeLoss	-1168995	USD
CY1999Q2	us-gaap	Stockholders Equity StockholdersEquity	912166	USD
CY2000	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	-260595	USD
CY2000	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	1475927	USD
CY2001	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	308619	USD
CY2000Q2	us-gaap	Stockholders Equity StockholdersEquity	1518558	USD
CY2001Q2	us-gaap	Stockholders Equity StockholdersEquity	-206713	USD
CY2002	snti	Issuance Of Common Stock And Warrants Value IssuanceOfCommonStockAndWarrantsValue	6477500	USD
CY2002	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	-846444	USD
CY2004	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	-2099090	USD
CY2004	snti	Cumulative Effect Of Reclassification Of Warrants CumulativeEffectOfReclassificationOfWarrants	1913463	USD
CY2004	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	-378624	USD
CY2004	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	1826514	USD
CY2004	snti	Stock Issued During Period Value Stock Options And Warrants Exercised StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised	696649	USD
CY2004	us-gaap	Net Income Loss NetIncomeLoss	-3726951	USD
CY2004Q2	us-gaap	Stockholders Equity StockholdersEquity	4730975	USD
CY2005	us-gaap	Net Income Loss NetIncomeLoss	-2978918	USD
CY2006	us-gaap	Net Income Loss NetIncomeLoss	-3314885	USD
CY2007	us-gaap	Net Income Loss NetIncomeLoss	-3251697	USD
CY2005	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	-428863	USD
CY2007	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	-230483	USD
CY2005	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	-1715347	USD
CY2005	snti	Cumulative Effect Of Reclassification Of Warrants CumulativeEffectOfReclassificationOfWarrants	1579715	USD
CY2005	snti	Stock Issued During Period Value Stock Options And Warrants Exercised StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised	61125	USD
CY2005	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	974235	USD
CY2006	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	677000	USD
CY2007	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	970162	USD
CY2005Q2	us-gaap	Stockholders Equity StockholdersEquity	5589751	USD
CY2006Q2	us-gaap	Stockholders Equity StockholdersEquity	2951966	USD
CY2012	us-gaap	Noncash Contribution Expense NoncashContributionExpense	0	USD
CY2011	us-gaap	Noncash Contribution Expense NoncashContributionExpense	0	USD
	us-gaap	Noncash Contribution Expense NoncashContributionExpense	85179	USD
CY2013	us-gaap	Other Noncash Expense OtherNoncashExpense	0	USD
CY2012	us-gaap	Other Noncash Expense OtherNoncashExpense	0	USD
CY2011	us-gaap	Other Noncash Expense OtherNoncashExpense	0	USD
	us-gaap	Other Noncash Expense OtherNoncashExpense	131250	USD
CY2013	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	371591	USD
CY2012	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	472463	USD
CY2011	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	609239	USD
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	9022980	USD
CY2007Q2	us-gaap	Stockholders Equity StockholdersEquity	2689539	USD
CY2006	snti	Stock Issued During Period Value Stock Warrants Exercised StockIssuedDuringPeriodValueStockWarrantsExercised	100	USD
CY2007	snti	Stock Issued During Period Value Stock Warrants Exercised StockIssuedDuringPeriodValueStockWarrantsExercised	100	USD
CY2008	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	1536968	USD
CY2008	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	9340000	USD
CY2008	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	436508	USD
CY2008	us-gaap	Net Income Loss NetIncomeLoss	-4601490	USD
CY2008Q2	us-gaap	Stockholders Equity StockholdersEquity	9835679	USD
CY2009	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	506847	USD
CY2009	us-gaap	Net Income Loss NetIncomeLoss	-5726869	USD
CY2009Q2	us-gaap	Stockholders Equity StockholdersEquity	5667834	USD
CY2009	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	44933	USD
CY2009	snti	Stock Issued During Period Value Stock Warrants Exercised StockIssuedDuringPeriodValueStockWarrantsExercised	0	USD
CY2010	us-gaap	New Accounting Pronouncement Or Change In Accounting Principle Effect Of Change On Net Income NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfChangeOnNetIncome	-3200108	USD
CY2010	snti	Issuance Of Common Stock And Warrants Value IssuanceOfCommonStockAndWarrantsValue	1530000	USD
CY2010	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	-180862	USD
CY2010	snti	Stock Issued During Period Value Preferred Stock And Common Stock Warrants StockIssuedDuringPeriodValuePreferredStockAndCommonStockWarrants	11497000	USD
CY2010	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	-1759008	USD
CY2010	snti	Stock Issued During Period Value Stock Warrants Exercised StockIssuedDuringPeriodValueStockWarrantsExercised	10050	USD
CY2010	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	386639	USD
CY2010	snti	Repurchase Of Warrants During Period Value RepurchaseOfWarrantsDuringPeriodValue	-50000	USD
CY2010	us-gaap	Dividends Dividends	-230875	USD
CY2010	us-gaap	Net Income Loss NetIncomeLoss	-13383513	USD
CY2010Q2	us-gaap	Stockholders Equity StockholdersEquity	7981024	USD
CY2011Q2	us-gaap	Stockholders Equity StockholdersEquity	4517463	USD
CY2011	us-gaap	Dividends Dividends	-122252	USD
CY2012	us-gaap	Dividends Dividends	-114474	USD
CY2011	snti	Deemed Dividends On Preferred Stock DeemedDividendsOnPreferredStock	0	USD
CY2011	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1853419	USD
CY2012	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3371681	USD
CY2011	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	-197908	USD
CY2012	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	-143765	USD
CY2011	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	USD
CY2012	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	USD
CY2011	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	866235	USD
CY2011	snti	Reclassification Of Warrant Liabilities To Equity ReclassificationOfWarrantLiabilitiesToEquity	1173296	USD
CY2012	snti	Deemed Dividends On Preferred Stock DeemedDividendsOnPreferredStock	0	USD
CY2012	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	766004	USD
CY2013	us-gaap	Dividends Dividends	-20000	USD
CY2013	snti	Reclassification Of Warrant Liabilities To Equity ReclassificationOfWarrantLiabilitiesToEquity	326205	USD
CY2013	snti	Deemed Dividends On Preferred Stock DeemedDividendsOnPreferredStock	0	USD
CY2013	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	USD
CY2013	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	724693	USD
CY1998Q2	us-gaap	Stockholders Equity StockholdersEquity	0	USD
CY2010	snti	Deemed Dividends On Preferred Stock DeemedDividendsOnPreferredStock	0	USD
CY2004	snti	Issuance Of Common Stock And Warrants Value IssuanceOfCommonStockAndWarrantsValue	3642500	USD
CY2005	snti	Issuance Of Common Stock And Warrants Value IssuanceOfCommonStockAndWarrantsValue	3366829	USD
CY2007	snti	Issuance Of Common Stock And Warrants Value IssuanceOfCommonStockAndWarrantsValue	2249491	USD
CY2007	snti	Issuance Of Common Stock And Warrants Price Per Share IssuanceOfCommonStockAndWarrantsPricePerShare	1.135
CY2007	us-gaap	Equity Issuance Dates EquityIssuanceDates	2006-10-10
CY2007	snti	Common Stock Issued Upon Exercise Of Warrant Price Per Share CommonStockIssuedUponExerciseOfWarrantPricePerShare	0.01
CY2005	snti	Issuance Of Common Stock And Warrants Price Per Share IssuanceOfCommonStockAndWarrantsPricePerShare	2.11
CY2005	us-gaap	Equity Issuance Dates EquityIssuanceDates	2005-05-09
CY2013	us-gaap	Noncash Contribution Expense NoncashContributionExpense	0	USD
CY2012	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	USD
CY2011	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	10000000	USD
CY2013	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	0	USD
CY2012	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	0	USD
CY2011	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	0	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1227869	USD
CY2013	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	370696	USD
CY2012	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	102460	USD
CY2011	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	141269	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1919220	USD
CY2013	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	0	USD
CY2012	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	0	USD
CY2011	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	115869	USD
	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	115869	USD
CY2013	us-gaap	Paid In Kind Interest PaidInKindInterest	0	USD
CY2012	us-gaap	Paid In Kind Interest PaidInKindInterest	0	USD
CY2011	us-gaap	Paid In Kind Interest PaidInKindInterest	0	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	2003386	USD
CY2013	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	USD
CY2012	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	USD
CY2011	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	53800	USD
CY2013	us-gaap	Share Based Compensation ShareBasedCompensation	724693	USD
CY2012	us-gaap	Share Based Compensation ShareBasedCompensation	766004	USD
CY2011	us-gaap	Share Based Compensation ShareBasedCompensation	750366	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	12830646	USD
CY2013	us-gaap	Depreciation And Amortization DepreciationAndAmortization	293629	USD
CY2012	us-gaap	Depreciation And Amortization DepreciationAndAmortization	258023	USD
CY2011	us-gaap	Depreciation And Amortization DepreciationAndAmortization	143274	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1393934	USD
CY2013	snti	Deferred Rent DeferredRent	0	USD
CY2012	snti	Deferred Rent DeferredRent	0	USD
CY2011	snti	Deferred Rent DeferredRent	8060	USD
	snti	Deferred Rent DeferredRent	0	USD
CY2013	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	USD
CY2013	us-gaap	Increase Decrease In Deposits Outstanding IncreaseDecreaseInDepositsOutstanding	0	USD
CY2012	us-gaap	Increase Decrease In Deposits Outstanding IncreaseDecreaseInDepositsOutstanding	-7187	USD
CY2011	us-gaap	Increase Decrease In Deposits Outstanding IncreaseDecreaseInDepositsOutstanding	5171	USD
	us-gaap	Increase Decrease In Deposits Outstanding IncreaseDecreaseInDepositsOutstanding	5171	USD
CY2013	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	42806	USD
CY2012	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	34989	USD
CY2011	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2105	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	637320	USD
CY2013	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	112319	USD
CY2012	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-132333	USD
CY2011	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	41572	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	542541	USD
CY2013	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3902626	USD
CY2012	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4386049	USD
CY2011	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5391442	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-40925016	USD
CY2013	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	527761	USD
CY2012	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	446035	USD
CY2011	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	684399	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	6752473	USD
CY2013	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1281	USD
CY2012	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4461	USD
CY2011	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2026	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	185947	USD
CY2013	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-529042	USD
CY2012	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-450496	USD
CY2011	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-686425	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-6938420	USD
CY2013	snti	Proceeds From Government Grant ProceedsFromGovernmentGrant	0	USD
CY2012	snti	Proceeds From Government Grant ProceedsFromGovernmentGrant	0	USD
CY2011	snti	Proceeds From Government Grant ProceedsFromGovernmentGrant	0	USD
	snti	Proceeds From Government Grant ProceedsFromGovernmentGrant	99728	USD
CY2013	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	-12026	USD
CY2012	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	0	USD
CY2011	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	4264	USD
	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	2187082	USD
CY2013	snti	Proceeds From Issuance Of Preferred Stock And Warrants Net ProceedsFromIssuanceOfPreferredStockAndWarrantsNet	0	USD
CY2012	snti	Proceeds From Issuance Of Preferred Stock And Warrants Net ProceedsFromIssuanceOfPreferredStockAndWarrantsNet	0	USD
CY2011	snti	Proceeds From Issuance Of Preferred Stock And Warrants Net ProceedsFromIssuanceOfPreferredStockAndWarrantsNet	0	USD
	snti	Proceeds From Issuance Of Preferred Stock And Warrants Net ProceedsFromIssuanceOfPreferredStockAndWarrantsNet	10754841	USD
CY2013	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0	USD
CY2012	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0	USD
CY2011	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0	USD
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	2160986	USD
CY2013	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	USD
CY2012	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	USD
CY2011	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	USD
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	651781	USD
CY2013	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	4044663	USD
CY2012	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	3227916	USD
CY2011	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	1657261	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	29371846	USD
CY2013	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4032637	USD
CY2012	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3227916	USD
CY2011	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1661525	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	49465730	USD
CY2013	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-399031	USD
CY2012	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-1608629	USD
CY2011	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-4416342	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	1602294	USD
CY2011Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3609954	USD
CY2010Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8026296	USD
CY1998Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	0	USD
CY2013	snti	Gain Loss On Settlement Of Warrant Liabilities GainLossOnSettlementOfWarrantLiabilities	-1724546	USD
CY2012	snti	Gain Loss On Settlement Of Warrant Liabilities GainLossOnSettlementOfWarrantLiabilities	0	USD
CY2011	snti	Gain Loss On Settlement Of Warrant Liabilities GainLossOnSettlementOfWarrantLiabilities	0	USD
	snti	Gain Loss On Settlement Of Warrant Liabilities GainLossOnSettlementOfWarrantLiabilities	-1724546	USD
CY2013	us-gaap	Use Of Estimates UseOfEstimates	<table border="0" style="clear:both;width:100%; table-layout:fixed;"> <tr> <td></td> </tr> </table> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="clear:both;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt 0.25in; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <em><font style="FONT-SIZE: 10pt">Management Estimates and Judgments</font></em></div> <div style="clear:both;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt 0.25in; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="clear:both;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt 0.25in; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-SIZE: 10pt">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period.  The critical accounting policies that require management's most significant estimate and judgment are the assessment of the recoverability of intangible assets, the variables and method used to calculate stock-based compensation and warrant liabilities, and the valuation allowance on deferred tax assets.  Actual results experienced by the Company may differ from management's estimates.</font></div> </div>
CY2013	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<table border="0" style="clear:both;width:100%; table-layout:fixed;"> <tr> <td></td> </tr> </table> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="clear:both;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt 0.25in; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <em><font style="FONT-SIZE: 10pt">Concentrations of Credit Risk</font></em></div> <div style="clear:both;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt 0.25in; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="clear:both;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt 0.25in; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-SIZE: 10pt">The Company maintains its cash primarily in investment accounts within one large financial institution. The Federal Deposit Insurance Corporation insures these balances up to $<font style=" FONT-SIZE: 10pt">250,000</font> per bank. The Company has not experienced any losses on its bank deposits and believes these deposits do not expose the Company to any significant credit risk.</font></div> </div>
CY2013Q2	snti	Federal Deposit Insurance Corporation Insurance Limit Per Bank FederalDepositInsuranceCorporationInsuranceLimitPerBank	250000	USD
CY2013	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P17Y
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.008	pure
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.003	pure
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.004	pure
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.019	pure
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.013	pure
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.029	pure
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.67	pure
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.78	pure
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.03	pure
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.02	pure
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.05	pure
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.04	pure
CY2011Q2	snti	Number Of Diluted Warrants Outstanding NumberOfDilutedWarrantsOutstanding	55301226	shares
CY2013Q2	snti	Number Of Diluted Options Outstanding NumberOfDilutedOptionsOutstanding	23174770	shares
CY2012Q2	snti	Number Of Diluted Options Outstanding NumberOfDilutedOptionsOutstanding	15647742	shares
CY2013	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<table border="0" style="clear:both;width:100%; table-layout:fixed;"> <tr> <td></td> </tr> </table> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="clear:both;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt 0.25in; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-SIZE: 10pt"><em> Reclassifications</em></font></div> <div style="clear:both;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt 0.25in; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-SIZE: 10pt"></font> </div> <div style="clear:both;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt 0.25in; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-SIZE: 10pt"><font size="2">Certain accounts in the prior year financial statements have been reclassified, for comparative purposes, in order to conform with the presentation in the current year financial statements. These reclassifications have no effect on the previously reported net loss.</font></font></div> </div>
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12884446	USD
CY2013	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	724693	USD
CY2012	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	766004	USD
CY2011	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	750366	USD
CY2013Q2	snti	Common Stock To Be Issued Upon Conversion Of Convertible Preferred Stock CommonStockToBeIssuedUponConversionOfConvertiblePreferredStock	26666667	shares
CY2012Q2	snti	Common Stock To Be Issued Upon Conversion Of Convertible Preferred Stock CommonStockToBeIssuedUponConversionOfConvertiblePreferredStock	17611538	shares
CY2011Q2	snti	Common Stock To Be Issued Upon Conversion Of Convertible Preferred Stock CommonStockToBeIssuedUponConversionOfConvertiblePreferredStock	16300000	shares
CY2013Q2	snti	Number Of Diluted Warrants Outstanding NumberOfDilutedWarrantsOutstanding	28315612	shares
CY2012Q2	snti	Number Of Diluted Warrants Outstanding NumberOfDilutedWarrantsOutstanding	57225981	shares
CY2011Q2	snti	Number Of Diluted Options Outstanding NumberOfDilutedOptionsOutstanding	11348314	shares
CY2013Q2	snti	Potential Dilutive Shares Of Common Stock PotentialDilutiveSharesOfCommonStock	78157049	shares
CY2012Q2	snti	Potential Dilutive Shares Of Common Stock PotentialDilutiveSharesOfCommonStock	90485261	shares
CY2011Q2	snti	Potential Dilutive Shares Of Common Stock PotentialDilutiveSharesOfCommonStock	82949540	shares
CY2013Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	1602294	USD
CY2012Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	2001325	USD
CY2012Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	238796	USD
CY2011Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	711259	USD
CY2013	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues	459000	USD
CY2012	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues	0	USD
CY2013	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet	371591	USD
CY2012	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet	472463	USD
CY2013Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	0	USD
CY2013	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-326205	USD
CY2012	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	0	USD
CY2013	us-gaap	Depreciation Depreciation	2583	USD
CY2012	us-gaap	Depreciation Depreciation	2386	USD
CY2011	us-gaap	Depreciation Depreciation	2798	USD
	us-gaap	Depreciation Depreciation	181392	USD
CY2013Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	100008	USD
CY2012Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	98727	USD
CY2013Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1018299	USD
CY2012Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	727820	USD
CY2012Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	4121812	USD
CY2013Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	95453	USD
CY2012Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	92870	USD
CY2013	us-gaap	Legal Fees LegalFees	527761	USD
CY2012	us-gaap	Legal Fees LegalFees	446035	USD
CY2013	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	291046	USD
CY2012	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	255637	USD
CY2011	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	140476	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1212542	USD
CY2013Q2	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	2665436	USD
CY2012Q2	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	2209286	USD
CY2013Q2	us-gaap	Other Finite Lived Intangible Assets Gross OtherFiniteLivedIntangibleAssetsGross	1919360	USD
CY2012Q2	us-gaap	Other Finite Lived Intangible Assets Gross OtherFiniteLivedIntangibleAssetsGross	1912526	USD
CY2013Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	4584796	USD
CY2013Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3566497	USD
CY2012Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3393992	USD
CY2013Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	300000	USD
CY2013Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	300000	USD
CY2013Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	300000	USD
CY2013Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	300000	USD
CY2013Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	300000	USD
CY2010Q1	us-gaap	Line Of Credit Facility Interest Rate Description LineOfCreditFacilityInterestRateDescription	Line of Credit accrue interest at an annual rate of (i) the broker rate in effect at the interest date (which was 3.75% at June 30, 2013), plus (ii) 2.0%. There are no other conditions or fees associated with the Line of Credit
CY2010Q1	us-gaap	Line Of Credit Facility Interest Rate At Period End LineOfCreditFacilityInterestRateAtPeriodEnd	0.0375	pure
CY2010Q1	snti	Line Of Credit Spread Over Base Rate LineOfCreditSpreadOverBaseRate	0.0200	pure
CY2013	snti	Warrant Liability Estimated Likelihood Of Reset Percentage WarrantLiabilityEstimatedLikelihoodOfResetPercentage	0.75	pure
CY2013Q2	snti	Shares Of Common Stock Issued In Exchange For Warrants SharesOfCommonStockIssuedInExchangeForWarrants	36902192	shares
CY2013	snti	Number Of Warrants Exchanged NumberOfWarrantsExchanged	39687500	shares
CY2013Q2	snti	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	210696	USD
CY2012Q2	snti	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	113264	USD
CY2013Q2	snti	Accrued Dividends Current AccruedDividendsCurrent	20000	USD
CY2012Q2	snti	Accrued Dividends Current AccruedDividendsCurrent	114474	USD
CY2013Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	156844	USD
CY2012Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	141957	USD
CY2010Q1	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	3000000	USD
CY2013Q2	us-gaap	Line Of Credit Facility Amount Outstanding LineOfCreditFacilityAmountOutstanding	2187082	USD
CY2012Q2	us-gaap	Line Of Credit Facility Amount Outstanding LineOfCreditFacilityAmountOutstanding	2199108	USD
CY2013	us-gaap	Interest Expense Short Term Borrowings InterestExpenseShortTermBorrowings	122453	USD
CY2012	us-gaap	Interest Expense Short Term Borrowings InterestExpenseShortTermBorrowings	134549	USD
CY2011	us-gaap	Interest Expense Short Term Borrowings InterestExpenseShortTermBorrowings	110649	USD
CY2011Q2	snti	Exercise Price Of Warrants ExercisePriceOfWarrants	0.32
CY2010	snti	Proceeds From Issuance Of Preferred Stock And Warrants Net ProceedsFromIssuanceOfPreferredStockAndWarrantsNet	10754841	USD
CY2010Q2	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	35928125	shares
CY2013Q2	snti	Preferred Stock Stated Value Per Share PreferredStockStatedValuePerShare	1000
CY2013	us-gaap	Preferred Stock Dividend Rate Percentage PreferredStockDividendRatePercentage	0.1	pure
CY2013Q2	snti	Additional Common Shares Issuable Upon Conversion Of Convertible Stock AdditionalCommonSharesIssuableUponConversionOfConvertibleStock	23216667	shares
CY2013	snti	Share Based Compensation Shares Authorized Under Stock Option Plans Grants In Period Exercise Price Range Lower Range Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansGrantsInPeriodExercisePriceRangeLowerRangeLimit	0.04
CY2013	us-gaap	Preferred Stock Dividend Payment Terms PreferredStockDividendPaymentTerms	If the dividends are paid in shares of Common Stock, such shares will be priced at the lower of 90% of the average volume weighted-average price for the 20 trading days immediately preceding the payment date or $0.224. The dividends were subject to a 30% make whole provision.
CY2011Q3	snti	Additional Common Shares Issuable Upon Conversion Of Convertible Stock AdditionalCommonSharesIssuableUponConversionOfConvertibleStock	1800000	shares
CY2012Q1	snti	Additional Common Shares Issuable Upon Conversion Of Convertible Stock AdditionalCommonSharesIssuableUponConversionOfConvertibleStock	690171	shares
CY2013Q1	snti	Additional Common Shares Issuable Upon Conversion Of Convertible Stock AdditionalCommonSharesIssuableUponConversionOfConvertibleStock	6123077	shares
CY2011	snti	Share Based Compensation Shares Authorized Under Stock Option Plans Cancelled In Period Exercise Price Range Lower Range Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansCancelledInPeriodExercisePriceRangeLowerRangeLimit	0
CY2011	snti	Share Based Compensation Shares Authorized Under Stock Option Plans Cancelled In Period Exercise Price Range Upper Range Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansCancelledInPeriodExercisePriceRangeUpperRangeLimit	0
CY2011	snti	Share Based Compensation Shares Authorized Under Stock Option Plans Expirations In Period Exercise Price Range Lower Range Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExpirationsInPeriodExercisePriceRangeLowerRangeLimit	0.99
CY2011	snti	Share Based Compensation Shares Authorized Under Stock Option Plans Expirations In Period Exercise Price Range Upper Range Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExpirationsInPeriodExercisePriceRangeUpperRangeLimit	2.25
CY2011Q2	snti	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerLimit	0.26
CY2013Q2	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	33333	shares
CY2011	snti	Preferred Dividends Accrued Not Yet Paid PreferredDividendsAccruedNotYetPaid	122252	USD
CY2013Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights	0.35
CY2010Q4	snti	Additional Common Shares Issuable Upon Conversion Of Convertible Stock AdditionalCommonSharesIssuableUponConversionOfConvertibleStock	1109375	shares
CY2013	snti	Debt Instrument Convertible Beneficial Conversion Feature Initial Fair Value DebtInstrumentConvertibleBeneficialConversionFeatureInitialFairValue	15068031	USD
CY2013	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature	5330039	USD
CY2013Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	1125000	shares
CY2013Q2	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	135	shares
CY2012	snti	Preferred Dividends Accrued Not Yet Paid PreferredDividendsAccruedNotYetPaid	114474	USD
CY2013Q2	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	1125000	shares
CY2010	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants	11497000	USD
CY2010	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	-1759008	USD
CY2010	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	9737992	USD
CY2011	snti	Share Based Compensation Shares Authorized Under Stock Option Plans Grants In Period Exercise Price Range Lower Range Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansGrantsInPeriodExercisePriceRangeLowerRangeLimit	0.26
CY2011	snti	Share Based Compensation Shares Authorized Under Stock Option Plans Grants In Period Exercise Price Range Upper Range Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansGrantsInPeriodExercisePriceRangeUpperRangeLimit	0.32
CY2011	snti	Share Based Compensation Shares Authorized Under Stock Option Plans Exercised In Period Exercise Price Range Lower Range Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisedInPeriodExercisePriceRangeLowerRangeLimit	0
CY2011	snti	Share Based Compensation Shares Authorized Under Stock Option Plans Exercised In Period Exercise Price Range Upper Range Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisedInPeriodExercisePriceRangeUpperRangeLimit	0
CY2011Q2	snti	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperLimit	4.00
CY2012	snti	Share Based Compensation Shares Authorized Under Stock Option Plans Grants In Period Exercise Price Range Lower Range Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansGrantsInPeriodExercisePriceRangeLowerRangeLimit	0.20
CY2012	snti	Share Based Compensation Shares Authorized Under Stock Option Plans Grants In Period Exercise Price Range Upper Range Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansGrantsInPeriodExercisePriceRangeUpperRangeLimit	0.26
CY2012	snti	Share Based Compensation Shares Authorized Under Stock Option Plans Exercised In Period Exercise Price Range Lower Range Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisedInPeriodExercisePriceRangeLowerRangeLimit	0
CY2012	snti	Share Based Compensation Shares Authorized Under Stock Option Plans Exercised In Period Exercise Price Range Upper Range Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisedInPeriodExercisePriceRangeUpperRangeLimit	0
CY2012	snti	Share Based Compensation Shares Authorized Under Stock Option Plans Cancelled In Period Exercise Price Range Lower Range Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansCancelledInPeriodExercisePriceRangeLowerRangeLimit	0
CY2012	snti	Share Based Compensation Shares Authorized Under Stock Option Plans Cancelled In Period Exercise Price Range Upper Range Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansCancelledInPeriodExercisePriceRangeUpperRangeLimit	0
CY2012	snti	Share Based Compensation Shares Authorized Under Stock Option Plans Expirations In Period Exercise Price Range Lower Range Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExpirationsInPeriodExercisePriceRangeLowerRangeLimit	1.50
CY2012	snti	Share Based Compensation Shares Authorized Under Stock Option Plans Expirations In Period Exercise Price Range Upper Range Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExpirationsInPeriodExercisePriceRangeUpperRangeLimit	4.00
CY2012Q2	snti	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerLimit	0.20
CY2013	snti	Share Based Compensation Shares Authorized Under Stock Option Plans Cancelled In Period Exercise Price Range Lower Range Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansCancelledInPeriodExercisePriceRangeLowerRangeLimit	0
CY2013	snti	Share Based Compensation Shares Authorized Under Stock Option Plans Grants In Period Exercise Price Range Upper Range Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansGrantsInPeriodExercisePriceRangeUpperRangeLimit	0.18
CY2013	snti	Share Based Compensation Shares Authorized Under Stock Option Plans Exercised In Period Exercise Price Range Lower Range Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisedInPeriodExercisePriceRangeLowerRangeLimit	0
CY2013	snti	Share Based Compensation Shares Authorized Under Stock Option Plans Exercised In Period Exercise Price Range Upper Range Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisedInPeriodExercisePriceRangeUpperRangeLimit	0
CY2013	snti	Share Based Compensation Shares Authorized Under Stock Option Plans Cancelled In Period Exercise Price Range Upper Range Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansCancelledInPeriodExercisePriceRangeUpperRangeLimit	0.23
CY2013	snti	Share Based Compensation Shares Authorized Under Stock Option Plans Expirations In Period Exercise Price Range Lower Range Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExpirationsInPeriodExercisePriceRangeLowerRangeLimit	1.09
CY2013	snti	Share Based Compensation Shares Authorized Under Stock Option Plans Expirations In Period Exercise Price Range Upper Range Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExpirationsInPeriodExercisePriceRangeUpperRangeLimit	2.35
CY2013Q2	snti	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerLimit	0.04
CY2013Q2	snti	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperLimit	3.45
CY2013	snti	Employee Stock Purchase Plan Minimum Percentage Of Common Stock Fair Value Defined To Purchase Shares By Eligible Participants EmployeeStockPurchasePlanMinimumPercentageOfCommonStockFairValueDefinedToPurchaseSharesByEligibleParticipants	0.15	pure
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3705000	shares
CY2012Q4	us-gaap	Stock Granted During Period Value Sharebased Compensation Gross StockGrantedDuringPeriodValueSharebasedCompensationGross	489060	USD
CY2013	snti	Probability To Achieve Employee Target Goals ProbabilityToAchieveEmployeeTargetGoals	0.55	pure
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	USD
CY2013	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y7M6D
CY2013Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0	USD
CY2013	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P7Y1M6D
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	4630353	shares
CY2013Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	739008	USD
CY2013	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P42M
CY2012Q2	snti	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperLimit	3.45
CY2010Q2	snti	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperLimit	4.00
CY2010Q2	snti	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerLimit	0.29
CY2013Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	28315612	shares
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	4579142	shares
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	5274428	shares
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	8966978	shares
CY2010Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7269172	shares
CY2011Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	11348314	shares
CY2012Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	15647742	shares
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	23174770	shares
CY2011	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2012	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2013	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2010Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.13
CY2011	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.26
CY2012	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.23
CY2013	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.14
CY2011	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2012	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2013	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2011Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.78
CY2012Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.50
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.35
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	500000	shares
CY2011	snti	Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod	0	shares
CY2012	snti	Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod	0	shares
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	975000	shares
CY2013	snti	Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod	-1152450	shares
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	287500	shares
CY2011	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0
CY2011	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	1.14
CY2012	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0
CY2012	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	2.32
CY2013	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.23
CY2013	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	2.02
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	16612179	shares
CY2012Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	10101055	shares
CY2011Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	7274422	shares
CY2012Q2	snti	Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedOptionsWeightedAverageGrantDateFairValue	0.25
CY2013	snti	Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Granted In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedOptionsGrantedInPeriodWeightedAverageGrantDateFairValue	0.11
CY2013	snti	Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedOptionsVestedInPeriodWeightedAverageGrantDateFairValue	0.13
CY2013	snti	Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Forfeited In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedOptionsForfeitedInPeriodWeightedAverageGrantDateFairValue	0.18
CY2013Q2	snti	Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedOptionsWeightedAverageGrantDateFairValue	0.16
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.41
CY2012Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.62
CY2011Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.04
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.11
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.17
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.33
CY2012Q2	snti	Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedOptionsOutstandingNumber	5546687	shares
CY2013	snti	Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedOptionsGrantsInPeriod	8966978	shares
CY2013	snti	Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedOptionsVestedInPeriod	-6798624	shares
CY2013	snti	Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedOptionsForfeituresInPeriod	-1152450	shares
CY2013Q2	snti	Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedOptionsOutstandingNumber	6562591	shares
CY2013	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	-0.340	pure
CY2012	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	-0.340	pure
CY2011	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	-0.340	pure
CY2013	snti	Effective Income Tax Rate Reconciliation Change In Fair Value Of Warrants EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrants	-0.020	pure
CY2012	snti	Effective Income Tax Rate Reconciliation Change In Fair Value Of Warrants EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrants	-0.032	pure
CY2011	snti	Effective Income Tax Rate Reconciliation Change In Fair Value Of Warrants EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrants	-0.028	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Deductions Other EffectiveIncomeTaxRateReconciliationDeductionsOther	-0.040	pure
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Deductions Other EffectiveIncomeTaxRateReconciliationDeductionsOther	-0.006	pure
CY2011	us-gaap	Effective Income Tax Rate Reconciliation Deductions Other EffectiveIncomeTaxRateReconciliationDeductionsOther	-0.019	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.390	pure
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.378	pure
CY2011	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.387	pure
CY2013	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2012	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2011	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Amortization EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAmortization	0.010	pure
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Amortization EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAmortization	0	pure
CY2011	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Amortization EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAmortization	0	pure
CY2013Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	19269000	USD
CY2012Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	17738000	USD
CY2013Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	2507000	USD
CY2012Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	2243000	USD
CY2013Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	44000	USD
CY2012Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	-42000	USD
CY2013Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	21820000	USD
CY2012Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	19939000	USD
CY2013Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	21820000	USD
CY2012Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	19939000	USD
CY2013Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2012Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2013	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2014-05-31
CY2013Q2	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	63261	USD
CY2013	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	69538	USD
CY2012	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	69174	USD
CY2011	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	88766	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	984270	USD
	snti	Advance Written Notice Period For Agreement Termination AdvanceWrittenNoticePeriodForAgreementTermination	P30D
CY2013	snti	Royalty Period RoyaltyPeriod	P10Y
CY2013	snti	Collaboration Agreement Funded Research And Development Incurred CollaborationAgreementFundedResearchAndDevelopmentIncurred	0	USD
CY2012	snti	Collaboration Agreement Funded Research And Development Incurred CollaborationAgreementFundedResearchAndDevelopmentIncurred	100000	USD
CY2011	snti	Collaboration Agreement Funded Research And Development Incurred CollaborationAgreementFundedResearchAndDevelopmentIncurred	205000	USD
CY1999Q3	snti	Collaborative Arrangement Agreement Research Funding Period CollaborativeArrangementAgreementResearchFundingPeriod	P5Y
CY1999Q3	snti	Collaboration Agreements Expiration Date CollaborationAgreementsExpirationDate	May 31, 2004
CY1999Q3	snti	Proceeds From Collaborative Agreement ProceedsFromCollaborativeAgreement	340000	USD
CY2013	snti	Collaborative Arrangement Up Front Payment Received CollaborativeArrangementUpFrontPaymentReceived	99728	USD
CY2012	snti	Collaborative Arrangement Up Front Payment Received CollaborativeArrangementUpFrontPaymentReceived	99728	USD
CY2011	snti	Collaborative Arrangement Up Front Payment Received CollaborativeArrangementUpFrontPaymentReceived	99728	USD
CY1999Q2	us-gaap	Collaborative Arrangement Rights And Obligations CollaborativeArrangementRightsAndObligations	The purpose of the Collaboration is to develop enhanced banana plants which will result in banana fruit with improved consumer- and grower-driven traits. The program had been performed as a joint collaboration whereby the Company paid for 50% of the research costs of the program.
CY2010Q4	us-gaap	Revenue From Grants RevenueFromGrants	244479	USD
CY2013	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	202808	USD
CY2012	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	11783	USD
CY2011	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	136644	USD
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	421922	USD
CY2013	snti	Warrants Issued For Financing Costs WarrantsIssuedForFinancingCosts	0	USD
CY2012	snti	Warrants Issued For Financing Costs WarrantsIssuedForFinancingCosts	0	USD
CY2011	snti	Warrants Issued For Financing Costs WarrantsIssuedForFinancingCosts	0	USD
	snti	Warrants Issued For Financing Costs WarrantsIssuedForFinancingCosts	690984	USD
CY2013	snti	Preferred Dividends Accrued Not Yet Paid PreferredDividendsAccruedNotYetPaid	20000	USD
	us-gaap	Interest Paid InterestPaid	494137	USD
	snti	Preferred Dividends Accrued Not Yet Paid PreferredDividendsAccruedNotYetPaid	20000	USD
CY2013	us-gaap	Interest Paid InterestPaid	122454	USD
CY2012	us-gaap	Interest Paid InterestPaid	134549	USD
CY2011	us-gaap	Interest Paid InterestPaid	110649	USD

Files In Submission

Name	View Source	Status
0001144204-13-050259-index-headers.html	Edgar Link	pending
0001144204-13-050259-index.html	Edgar Link	pending
0001144204-13-050259.txt	Edgar Link	pending
0001144204-13-050259-xbrl.zip	Edgar Link	pending
ex0077img-1.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
ft0001img-4.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R1.xml	Edgar Link	unprocessable
R10.htm	Edgar Link	pending
R10.xml	Edgar Link	unprocessable
R11.htm	Edgar Link	pending
R11.xml	Edgar Link	unprocessable
R12.htm	Edgar Link	pending
R12.xml	Edgar Link	unprocessable
R13.htm	Edgar Link	pending
R13.xml	Edgar Link	unprocessable
R14.htm	Edgar Link	pending
R14.xml	Edgar Link	unprocessable
R15.htm	Edgar Link	pending
R15.xml	Edgar Link	unprocessable
R16.htm	Edgar Link	pending
R16.xml	Edgar Link	unprocessable
R17.htm	Edgar Link	pending
R17.xml	Edgar Link	unprocessable
R18.htm	Edgar Link	pending
R18.xml	Edgar Link	unprocessable
R19.htm	Edgar Link	pending
R19.xml	Edgar Link	unprocessable
R2.htm	Edgar Link	pending
R2.xml	Edgar Link	unprocessable
R20.htm	Edgar Link	pending
R20.xml	Edgar Link	unprocessable
R21.htm	Edgar Link	pending
R21.xml	Edgar Link	unprocessable
R22.htm	Edgar Link	pending
R22.xml	Edgar Link	unprocessable
R23.htm	Edgar Link	pending
R23.xml	Edgar Link	unprocessable
R24.htm	Edgar Link	pending
R24.xml	Edgar Link	unprocessable
R25.htm	Edgar Link	pending
R25.xml	Edgar Link	unprocessable
R26.htm	Edgar Link	pending
R26.xml	Edgar Link	unprocessable
R27.htm	Edgar Link	pending
R27.xml	Edgar Link	unprocessable
R28.htm	Edgar Link	pending
R28.xml	Edgar Link	unprocessable
R29.htm	Edgar Link	pending
R29.xml	Edgar Link	unprocessable
R3.htm	Edgar Link	pending
R3.xml	Edgar Link	unprocessable
R30.htm	Edgar Link	pending
R30.xml	Edgar Link	unprocessable
R31.htm	Edgar Link	pending
R31.xml	Edgar Link	unprocessable
R32.htm	Edgar Link	pending
R32.xml	Edgar Link	unprocessable
R33.htm	Edgar Link	pending
R33.xml	Edgar Link	unprocessable
R34.htm	Edgar Link	pending
R34.xml	Edgar Link	unprocessable
R35.htm	Edgar Link	pending
R35.xml	Edgar Link	unprocessable
R36.htm	Edgar Link	pending
R36.xml	Edgar Link	unprocessable
R37.htm	Edgar Link	pending
R37.xml	Edgar Link	unprocessable
R38.htm	Edgar Link	pending
R38.xml	Edgar Link	unprocessable
R39.htm	Edgar Link	pending
R39.xml	Edgar Link	unprocessable
R4.htm	Edgar Link	pending
R4.xml	Edgar Link	unprocessable
R40.htm	Edgar Link	pending
R40.xml	Edgar Link	unprocessable
R41.htm	Edgar Link	pending
R41.xml	Edgar Link	unprocessable
R42.htm	Edgar Link	pending
R42.xml	Edgar Link	unprocessable
R43.htm	Edgar Link	pending
R43.xml	Edgar Link	unprocessable
R44.htm	Edgar Link	pending
R44.xml	Edgar Link	unprocessable
R45.htm	Edgar Link	pending
R45.xml	Edgar Link	unprocessable
R46.htm	Edgar Link	pending
R46.xml	Edgar Link	unprocessable
R47.htm	Edgar Link	pending
R47.xml	Edgar Link	unprocessable
R48.htm	Edgar Link	pending
R48.xml	Edgar Link	unprocessable
R49.htm	Edgar Link	pending
R49.xml	Edgar Link	unprocessable
R5.htm	Edgar Link	pending
R5.xml	Edgar Link	unprocessable
R50.htm	Edgar Link	pending
R50.xml	Edgar Link	unprocessable
R51.htm	Edgar Link	pending
R51.xml	Edgar Link	unprocessable
R52.htm	Edgar Link	pending
R52.xml	Edgar Link	unprocessable
R53.htm	Edgar Link	pending
R53.xml	Edgar Link	unprocessable
R54.htm	Edgar Link	pending
R54.xml	Edgar Link	unprocessable
R55.htm	Edgar Link	pending
R55.xml	Edgar Link	unprocessable
R56.htm	Edgar Link	pending
R56.xml	Edgar Link	unprocessable
R57.htm	Edgar Link	pending
R57.xml	Edgar Link	unprocessable
R58.htm	Edgar Link	pending
R58.xml	Edgar Link	unprocessable
R59.htm	Edgar Link	pending
R59.xml	Edgar Link	unprocessable
R6.htm	Edgar Link	pending
R6.xml	Edgar Link	unprocessable
R60.htm	Edgar Link	pending
R60.xml	Edgar Link	unprocessable
R61.htm	Edgar Link	pending
R61.xml	Edgar Link	unprocessable
R62.htm	Edgar Link	pending
R62.xml	Edgar Link	unprocessable
R7.htm	Edgar Link	pending
R7.xml	Edgar Link	unprocessable
R8.htm	Edgar Link	pending
R8.xml	Edgar Link	unprocessable
R9.htm	Edgar Link	pending
R9.xml	Edgar Link	unprocessable
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
snti-20130630.xml	Edgar Link	completed
snti-20130630.xsd	Edgar Link	pending
snti-20130630_cal.xml	Edgar Link	unprocessable
snti-20130630_def.xml	Edgar Link	unprocessable
snti-20130630_lab.xml	Edgar Link	unprocessable
snti-20130630_pre.xml	Edgar Link	unprocessable
v353644_10k.htm	Edgar Link	pending
v353644_ex10-14.htm	Edgar Link	pending
v353644_ex10-24.htm	Edgar Link	pending
v353644_ex10-29.htm	Edgar Link	pending
v353644_ex10-45.htm	Edgar Link	pending
v353644_ex23-1.htm	Edgar Link	pending
v353644_ex31-1.htm	Edgar Link	pending
v353644_ex31-2.htm	Edgar Link	pending
v353644_ex32-1.htm	Edgar Link	pending
v353644_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ELOX
Eloxx Pharmaceuticals, Inc. Stock $elox

2013 Q3 Form 10-K Financial Statement

#000114420413050259 Filed on September 11, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELOX Eloxx Pharmaceuticals, Inc. Stock $elox

2013 Q3 Form 10-K Financial Statement

#000114420413050259 Filed on September 11, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELOX
Eloxx Pharmaceuticals, Inc. Stock $elox